{"ticker": {"uuid": "16127704-a25b-4ff5-9df7-400c22a6fe11", "symbol": "GNTA", "name": "Genenta Science SpA ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Genenta Science Regains Full Effectiveness of Corporate Purpose Amendment After Milan Court Ruling", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNYkxFLVFhQ1VlUGhlVngxY0xIdVRZTm01anJKbzRUcXBqNFY4VmtPS0lxZ2lXWkVjUldCUndtWUk2OEFIdkhWdnlJXzFyb2tqUi15SnBNN0d1X2ZBZVpvOGZRNTBWelBfNTB5X3ZiNzJUUlNuMldVTWZlY1pobkZtVXhScldrRzBQSUNEZ29LV293c0R6dDV2cTFseXhZZVJWeU1IcEw5aVN0REpPVjBnbVgxT25KOU8zQ0VvVnprdTZwU0RKUGpJZzN4b2h3Y1BENUZjR0Q3YjMwajdKejA2VHdaVDI?oc=5", "source_name": "TipRanks", "published_at": "2026-07-14T20:37:28+00:00", "published_display": "14 Jul 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Court restores Genenta Science (GNTA) corporate purpose amendment", "summary": "Genenta Science S.p.A. announced that the Court of Milan has revoked a preliminary order that had suspended the effectiveness of an amendment to its corporate purpose, making the amendment fully effective again. The court granted Genenta's appeal, noting the company's interest in", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-33907c1caf16.html", "source_name": "Stock Titan", "published_at": "2026-07-14T19:46:27", "published_display": "14 Jul 2026 19:46", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Genenta Science Faces Selling Pressure as Shares Drop 5.66% \u2013 Key Levels in Focus - Social Sentiment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQVWFjUDdsQlc5SmhCelJlRHhqdGxPM2t3NFlnd29vbExOQlVFMzlQX2ZQcFhtUENzTmpNYWpXRFZiaE5ZeXM0aVRNX0tESWJEVXlYMV8wblVuUUZjWnN2cWVnVjlsQmJzQm5EWWdOYXRZMVBZV1FFZjhCU21abFl5dlZhdnRWRlRkNUtqdGFlNlZUY0pkNThZdmNPZG1iRWNPQ1A1VEdBYUxFMlR5ZG0yenJVMEt1bDZEbDRWVFBCZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-12T22:40:48+00:00", "published_display": "12 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (Nasdaq:GNTA) - Stock Analysis", "summary": "This report provides a stock analysis for Genenta Science (GNTA), a clinical-stage biotechnology company developing gene therapies for solid tumors. It highlights significant risks including declining earnings, low revenue, share price volatility, and shareholder dilution. Despit", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gnta/genenta-science", "source_name": "Simply Wall Street", "published_at": "2026-07-10T05:10:40", "published_display": "10 Jul 2026 05:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science(GNTA) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOQ2VkWEJRRjBQY24tVXJJQjIxc0Z4SmVWTVFXcHZpeUlBWjBwc3lOYkVBNjg1bzhXZEkwREh6UzctZmN4c29JR1hqa0d3VkQ4VzFtaTNlNWQ0UWxhNGE5U18zMXliU2wxcUVQaXJnSDYzcXg0bW9VVUJUQ1ZDY0ttMGJjRkJSbGJEWjZSRV9PYmNNOUxzcW93ZFg3dHh5Mng2VGpjc2Q0eExuM1pWWWJZR2RFUkdzaFE1ZFlCcW9IN1lKUlRtU1Y1Q3pzOWljdFBEMmFvNVJmOHplclBQWTl1U3NodUg0ZDdySWp1dmRHenRXaUp1SFJPNnQ4ZElsaU9HMGVqMlZTMjhVaWQxWGRNM2NMRzNaVkRjVEVUX0VlSWFiRFkyazg1WHR4U0c?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T16:10:21+00:00", "published_display": "08 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Genenta Science S.p.A. \u2013 NASDAQ:GNTA", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Genenta Science S.p.A. (NASDAQ: GNTA) on the TradingView platform. The content is primarily a data display from TradingView's financial section, indicating the company's valuation. No further financial ana", "url": "https://www.tradingview.com/symbols/NASDAQ-GNTA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T16:39:14", "published_display": "02 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Genenta Science S.p.A. \u2013 NASDAQ:GNTA", "summary": "The article title mentions \"Price to book forward of Genenta Science S.p.A. - NASDAQ:GNTA,\" indicating it is a financial data point for the company Genenta Science S.p.A., which is listed on NASDAQ. The content, however, appears to be an empty or placeholder page from TradingView", "url": "https://www.tradingview.com/symbols/NASDAQ-GNTA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T07:40:44", "published_display": "02 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science Faces Court-Ordered Suspension of Corporate Purpose Amendment While Voting Rights Reform Stands", "summary": "Genenta Science S.p.A. announced that the Court of Milan upheld a shareholder resolution introducing a multiple voting rights mechanism, supporting long-term shareholding stability. However, the court suspended an October 2025 resolution that broadened Genenta\u2019s corporate purpose", "url": "https://www.theglobeandmail.com/investing/markets/stocks/GNTA/pressreleases/3017353/genenta-science-faces-court-ordered-suspension-of-corporate-purpose-amendment-while-voting-rights-reform-stands/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T04:10:46", "published_display": "02 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) completes S\u00f2phia High Tech deal and resets key vote", "summary": "Genenta Science (GNTA) has completed its acquisition of a majority equity interest in S\u00f2phia High Tech S.r.l. Shareholders approved the 2025 financial statements and appointed five directors, with co-founder Pierluigi Paracchi re-appointed as Chairman. An Extraordinary Shareholde", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-9c7181ccbefc.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:13", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Genenta Science SpA Sponsored ADR \u2013 FWB:K5F", "summary": "This article provides financial data for Genenta Science SpA Sponsored ADR (FWB:K5F), specifically focusing on its Enterprise Value to EBITDA forward metric. The data is presented by TradingView and indicates a market closed status with no recent trades for the stock on the Frank", "url": "https://www.tradingview.com/symbols/FWB-K5F/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T23:09:42", "published_display": "28 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Genenta Science S.p.A. \u2013 NASDAQ:GNTA", "summary": "This article provides financial information for Genenta Science S.p.A. (NASDAQ:GNTA), specifically focusing on its forward price-to-sales ratio. It appears to be a financial data snippet from TradingView, displaying key metrics for the pharmaceutical company.", "url": "https://www.tradingview.com/symbols/NASDAQ-GNTA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T16:09:42", "published_display": "28 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Genenta Science SpA Sponsored ADR \u2013 FWB:K5F", "summary": "This page displays information regarding the enterprise value to revenue forward for Genenta Science SpA Sponsored ADR (FWB:K5F) on the Frankfurt Stock Exchange. The market was closed, and no trades were recorded. The content is primarily a financial data display from TradingView", "url": "https://www.tradingview.com/symbols/FWB-K5F/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:41:04", "published_display": "28 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Genenta Science S.p.A. \u2013 NASDAQ:GNTA", "summary": "This article focuses on the \"Price to earnings forward\" metric for Genenta Science S.p.A. (NASDAQ: GNTA). It appears to be a financial data page from TradingView, providing an overview of the company's financial information. The content itself, however, does not present any speci", "url": "https://www.tradingview.com/symbols/NASDAQ-GNTA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T05:41:04", "published_display": "28 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta (GNTA) faces court suspension of broad corporate purpose change", "summary": "The Court of Milan has issued an interim order regarding Genenta Science S.p.A. (GNTA), denying the suspension of its multiple voting rights mechanism but temporarily suspending a resolution that broadly amended the company's corporate purpose. The court cited concerns that the c", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-c9f76e01f6bc.html", "source_name": "Stock Titan", "published_at": "2026-06-26T19:39:59", "published_display": "26 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science Sets CEO Severance Terms and Narrows Non-Compete in June 2026", "summary": "Genenta Science S.p.A. (GNTA) has formalized a severance agreement with CEO Pierluigi Paracchi, providing him with a lump-sum payment equivalent to twelve months of his gross remuneration plus a potential 40% annual bonus upon qualifying termination events. The company also narro", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2649620/genenta-science-sets-ceo-severance-terms-and-narrows-non-compete-in-june-2026/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T12:11:34", "published_display": "26 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science SpA Sponsored ADR Actuals & Estimates (NASDAQ:GNTA)", "summary": "The article provides an overview of Genenta Science S.p.A. (NASDAQ:GNTA) on TradingView, focusing on its financial actuals and estimates. It highlights access to reported financial data, analyst estimates across various financial statements, and offers tools to compare actual res", "url": "https://www.tradingview.com/symbols/NASDAQ-GNTA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:11:50", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (NASDAQ: GNTA) revises CEO severance package and non-compete", "summary": "Genenta Science (NASDAQ: GNTA) has updated the severance package and non-compete clause for its CEO, Pierluigi Paracchi, as detailed in a recent 6-K filing. The new \"Parachute Agreement\" stipulates a lump-sum severance payment equivalent to twelve months of his gross remuneration", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-ec26505c341d.html", "source_name": "Stock Titan", "published_at": "2026-06-24T12:41:42", "published_display": "24 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Calls June 29 Shareholder Vote on Name Change, Capital Moves and Reverse Split", "summary": "Genenta Science SpA has scheduled an Ordinary and Extraordinary Shareholders\u2019 Meeting for June 29, 2026, to address significant corporate changes. Shareholders will vote on approving 2025 financial statements, appointing a new Board of Directors, and authorizing share repurchases", "url": "https://www.theglobeandmail.com/investing/markets/stocks/GNTA-Q/pressreleases/2537887/genenta-calls-june-29-shareholder-vote-on-name-change-capital-moves-and-reverse-split/", "source_name": "The Globe and Mail", "published_at": "2026-06-18T20:10:11", "published_display": "18 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science SPA (GNTA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE00T3F4Mk9jRlZ3YXRrTHMxSW5zVmJwZXNzcXprQ1RBS2N4UFRLanE5R2wwV2RRWFhUbjdVYk5kTW5LVS13dHhGcGQxVmlSNVR1d0xQQ1dlYTdIT1RHNFlRMk1FOU11SGpJQVJKWHk0d2o?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T10:22:19+00:00", "published_display": "18 Jun 2026 10:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science SPA (GNTA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Genenta Science SPA (GNTA) as presented on TradingKey. It indicates that GNTA has not distributed any dividends over the past five years and has no recorded stock splits. The page also displays current stoc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnta/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:24", "published_display": "18 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science SPA (GNTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Genenta Science SPA (GNTA), but explicitly states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company. It lists the company's curr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnta/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:24", "published_display": "18 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science SPA (GNTA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Genenta Science SPA (GNTA), highlighting its current stock price, market cap, and analyst target price. While it notes the current stock details, it indicates that relevant data for financial forecasting metrics like EPS, Revenue, an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnta/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:11", "published_display": "18 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science SPA (GNTA) Institutional Confidence", "summary": "This article from TradingKey provides an \"Institutional Confidence\" overview for Genenta Science SPA (GNTA), listing key shareholders and their respective shareholdings, including recent changes. The stock closed at $1.820 USD, down 2.67%, and has a market cap of $43.41M. Citadel", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnta/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:11", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science Regains Compliance with Nasdaq Minimum Bid Price Rule", "summary": "Genenta Science (GNTA) announced it has regained compliance with Nasdaq's minimum bid price rule of $1.00 per share, resolving a previous non-compliance issue. This ensures the company's continued listing on the Nasdaq Capital Market, preserving market confidence and access to pu", "url": "https://www.theglobeandmail.com/investing/markets/stocks/GNTA-Q/pressreleases/2517030/genenta-science-regains-compliance-with-nasdaq-minimum-bid-price-rule/", "source_name": "The Globe and Mail", "published_at": "2026-06-17T13:10:38", "published_display": "17 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) sets June meeting on name change and reverse split", "summary": "Genenta Science (GNTA) has scheduled an all-virtual ordinary and extraordinary shareholders' meeting for June 29, 2026, with a potential second call on June 30, 2026. Shareholders will vote on approving financial statements, appointing a new Board, authorizing treasury share tran", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-4a3aa3bf231f.html", "source_name": "Stock Titan", "published_at": "2026-06-17T13:09:12", "published_display": "17 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science regains compliance with Nasdaq minimum bid price rule By Investing.com", "summary": "Genenta Science S.p.A. announced it has regained compliance with Nasdaq's minimum bid price requirement. The company's American Depositary Shares (ADSs) maintained a closing bid price at or above $1.00 for ten consecutive business days, resolving a previous non-compliance issue. ", "url": "https://za.investing.com/news/sec-filings/genenta-science-regains-compliance-with-nasdaq-minimum-bid-price-rule-93CH-4330849", "source_name": "Investing.com South Africa", "published_at": "2026-06-16T19:40:49", "published_display": "16 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (NASDAQ: GNTA) regains Nasdaq minimum bid price compliance", "summary": "Genenta Science (NASDAQ: GNTA) has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company's American Depositary Shares (ADSs) traded at or above $1.00 per share for 10 consecutive business days from June 1-12, 2026, resolving a previous", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-575d6471741f.html", "source_name": "Stock Titan", "published_at": "2026-06-16T13:39:21", "published_display": "16 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GNTA - Genenta Science SpA ADR Options", "summary": "This page provides an overview of Genenta Science SpA ADR (GNTA) stock options, including financial data, performance metrics, and key statistics. It details the company's market cap, enterprise value, income, sales, and various ratios, alongside insider and institutional ownersh", "url": "https://finviz.com/stock?t=GNTA&ty=oc", "source_name": "Finviz", "published_at": "2026-06-12T04:40:46", "published_display": "12 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GNTA Stock Sees Volatile Spike As Traders Eye Key Levels", "summary": "Genenta Science S.p.A. (NASDAQ: GNTA) stock surged over 100% due to progress in its oncology trial, attracting significant trader attention. The company, a micro-cap biotech, has little revenue but holds a solid balance sheet, making it a speculative bet on future potential rathe", "url": "https://www.timothysykes.com/news/genenta-science-spa-gnta-news-2026_06_01/", "source_name": "Timothy Sykes", "published_at": "2026-06-01T13:09:44", "published_display": "01 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GNTA Stock Explodes On Volume As Traders Scan Biotech Charts", "summary": "Genenta Science S.p.A. (GNTA) stock surged by 85.5%, driven by regulatory and clinical progress, turning it into a low-float momentum play for active traders. Despite its small revenue, GNTA has a solid balance sheet and trades near its book value, making its chart action and vol", "url": "https://stockstotrade.com/news/genenta-science-spa-gnta-news-2026_06_01/", "source_name": "StocksToTrade", "published_at": "2026-06-01T10:02:00", "published_display": "01 Jun 2026 10:02", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science Closes All-Share Acquisition of Remaining Stake in A.T.C.", "summary": "Genenta Science has completed an all-share acquisition of the remaining 80.5% stake in A.T.C. S.r.l., solidifying its full ownership. The \u20ac9.6 million purchase was settled by issuing new Genenta ordinary shares to A.T.C. shareholders, who are subject to a 36-month lock-up period ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/GNTA-Q/pressreleases/2219172/genenta-science-closes-all-share-acquisition-of-remaining-stake-in-a-t-c/", "source_name": "The Globe and Mail", "published_at": "2026-05-31T13:08:56", "published_display": "31 May 2026 13:08", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) Surges on High Volume: Key Levels and Potential Drivers - Quality Factor", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPcl95bUw0dVI3aHl6RXc4Y1FsQkp6QS1HcFZmS1BoeE11YW81Uko5MFhjUzk0V2JlQThKdjl2VzhYTy1ndnMyamFOclBuZnJUODVTXzQyUFVGWWlKY19WdXVRODBlZmlUbmNrU2l1TEJkVG9nd01Md2VDM1hGbkxYLWxESUNXcEFzS1Y1MmxKemVYR09qTHItYWs4U1BCeUZWWUJYbFZFcUVRY3FUYVV4WDY3Z20wa0JMaHo2UVlRbw?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) takes full control by acquiring remaining 80.5% of A.T.C.", "summary": "Genenta Science (GNTA) has acquired the remaining 80.5% equity ownership of A.T.C. S. from its existing shareholders, taking full control. The transaction, finalized on May 29, 2026, was governed by an Amendment Agreement and approved by Genenta's board on May 18, 2026. Key terms", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-945ff04241b8.html", "source_name": "Stock Titan", "published_at": "2026-05-29T19:38:44", "published_display": "29 May 2026 19:38", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) Surges 9%: Testing Key Resistance at $0.95 - Trend Continuation Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPdGhlWUVTaG5zRTE1czZqRW9oZGp4eFphcWtQQ045WjYxcDdxU09TTEhSLUJpaFBpOVlBX3JPMDFFeUdTWDVEaGh4Ry1rZ2VieFJpTlp3VV9EZ2lleVh6NUNDRURKTXlfRURWS2dzeUZmX2RZTHZ2RGNPMDRNUVRNSlRfNFZuMTQyUTZnOHN1T1hWU1Mtbk8tMmFTLXluS1dHLVN1X05EbWxBZzAzaVB3?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) Surges 9%: Testing Key Resistance at $0.95 - Median Line", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOMnF3bDZrS3dZQ0N4b042QmtCcGx3dDM1S3dqYnV4MEVfSm1nRnJ6NGVETWVNNlptT2hvR2czTGJqbjN2MHNmMmFGWG40M01JUlVyaWl4Z3ZBYUUyY1NxZjBHUVBVMzZkdW5OZXNWQjl6Smk3Y0R6cUdpSXJwZlpGbVlHdnlsYlh0S1BmZzdNRTVvTUU2c0p1dkEyZUV1SjRYTFE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) Holds Steady at $0.60 Amid Low Volatility - Mid Cap Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNaDBVRDRUZm10aUQ0RzRQZXJHbFdnY0xfd3FnaTBaenNzZ0xxbWtmVTlSSUdGUjloQ0k5cWh0aTRPZUZIZGNRakdVdHJJSEdQdUhUTmRvNXFqRTl2UllEelh1V0ZYWDFPZm05RlotUHk1dzlBazJLVzgzc0dxS2FkWGtpQlFIVEpuRzZid2NlN3dHMWpqMkVONlV6Vm94V3J6SG5zeU02c25FbDQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Genenta signs Definitive Agreements with Sophia High Tech", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/genenta-signs-definitive-agreements-sophia-110000653.html", "source_name": "GlobeNewswire", "published_at": "2026-04-23T11:00:00+00:00", "published_display": "23 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQaUJfcTdWRC1BYU5iUW5SSXM4cENlak1JLTBERDhfeUtsNVpaOVluS0VqTnFJWkwyTnhkVUJ5ZnVtTjRPcTB0YnhzWlVHUHF6eUcwa1VVVTlwOEZwQ3U2WndDdHJXR3dLN0xxbTJVR294akF2R0xyV2hXUEYzckRlNy1VRW41dw?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science Spa (GNTA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1UcEdKXzN4em9ySWxudzg1VXpzM3d4VGJ2Rk9FNHFEc2tvTGU0bjBUZmlkdUZJSTZoT0laRi1JSTJ3V1RLaFBqUnh4WDB1MGp5ZGpR?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T17:33:47+00:00", "published_display": "24 Apr 2025 17:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science S.p.A.: Shareholders Board Members Managers and Company Profile | US36870W1009", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNVHZZNDkwRU1maXF1Vlh6YVJKcldWMXhVWTFKdzZfRnMzaE8xNVE0RXUwTVVtRnNFRUNuUzdDYzFXSEhWSzZRNGdoTU9EMThxZWtqb01rQUd1YVNQVTRUNXFVYTdmMmRlVWJDRlFWRVpvODlKT2ZNemFtbXhTR19xa2hVVkNRejh2cTI0?oc=5", "source_name": "marketscreener.com", "published_at": "2021-12-17T21:21:52+00:00", "published_display": "17 Dec 2021 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Genenta Science Regains Full Effectiveness of Corporate Purpose Amendment After Milan Court Ruling", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNYkxFLVFhQ1VlUGhlVngxY0xIdVRZTm01anJKbzRUcXBqNFY4VmtPS0lxZ2lXWkVjUldCUndtWUk2OEFIdkhWdnlJXzFyb2tqUi15SnBNN0d1X2ZBZVpvOGZRNTBWelBfNTB5X3ZiNzJUUlNuMldVTWZlY1pobkZtVXhScldrRzBQSUNEZ29LV293c0R6dDV2cTFseXhZZVJWeU1IcEw5aVN0REpPVjBnbVgxT25KOU8zQ0VvVnprdTZwU0RKUGpJZzN4b2h3Y1BENUZjR0Q3YjMwajdKejA2VHdaVDI?oc=5", "source_name": "TipRanks", "published_at": "2026-07-14T20:37:28+00:00", "published_display": "14 Jul 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Court restores Genenta Science (GNTA) corporate purpose amendment", "summary": "Genenta Science S.p.A. announced that the Court of Milan has revoked a preliminary order that had suspended the effectiveness of an amendment to its corporate purpose, making the amendment fully effective again. The court granted Genenta's appeal, noting the company's interest in", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-33907c1caf16.html", "source_name": "Stock Titan", "published_at": "2026-07-14T19:46:27", "published_display": "14 Jul 2026 19:46", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science Faces Selling Pressure as Shares Drop 5.66% \u2013 Key Levels in Focus - Social Sentiment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQVWFjUDdsQlc5SmhCelJlRHhqdGxPM2t3NFlnd29vbExOQlVFMzlQX2ZQcFhtUENzTmpNYWpXRFZiaE5ZeXM0aVRNX0tESWJEVXlYMV8wblVuUUZjWnN2cWVnVjlsQmJzQm5EWWdOYXRZMVBZV1FFZjhCU21abFl5dlZhdnRWRlRkNUtqdGFlNlZUY0pkNThZdmNPZG1iRWNPQ1A1VEdBYUxFMlR5ZG0yenJVMEt1bDZEbDRWVFBCZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-12T22:40:48+00:00", "published_display": "12 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (Nasdaq:GNTA) - Stock Analysis", "summary": "This report provides a stock analysis for Genenta Science (GNTA), a clinical-stage biotechnology company developing gene therapies for solid tumors. It highlights significant risks including declining earnings, low revenue, share price volatility, and shareholder dilution. Despit", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gnta/genenta-science", "source_name": "Simply Wall Street", "published_at": "2026-07-10T05:10:40", "published_display": "10 Jul 2026 05:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science(GNTA) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOQ2VkWEJRRjBQY24tVXJJQjIxc0Z4SmVWTVFXcHZpeUlBWjBwc3lOYkVBNjg1bzhXZEkwREh6UzctZmN4c29JR1hqa0d3VkQ4VzFtaTNlNWQ0UWxhNGE5U18zMXliU2wxcUVQaXJnSDYzcXg0bW9VVUJUQ1ZDY0ttMGJjRkJSbGJEWjZSRV9PYmNNOUxzcW93ZFg3dHh5Mng2VGpjc2Q0eExuM1pWWWJZR2RFUkdzaFE1ZFlCcW9IN1lKUlRtU1Y1Q3pzOWljdFBEMmFvNVJmOHplclBQWTl1U3NodUg0ZDdySWp1dmRHenRXaUp1SFJPNnQ4ZElsaU9HMGVqMlZTMjhVaWQxWGRNM2NMRzNaVkRjVEVUX0VlSWFiRFkyazg1WHR4U0c?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T16:10:21+00:00", "published_display": "08 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Genenta Science S.p.A. \u2013 NASDAQ:GNTA", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Genenta Science S.p.A. (NASDAQ: GNTA) on the TradingView platform. The content is primarily a data display from TradingView's financial section, indicating the company's valuation. No further financial ana", "url": "https://www.tradingview.com/symbols/NASDAQ-GNTA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T16:39:14", "published_display": "02 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Genenta Science S.p.A. \u2013 NASDAQ:GNTA", "summary": "The article title mentions \"Price to book forward of Genenta Science S.p.A. - NASDAQ:GNTA,\" indicating it is a financial data point for the company Genenta Science S.p.A., which is listed on NASDAQ. The content, however, appears to be an empty or placeholder page from TradingView", "url": "https://www.tradingview.com/symbols/NASDAQ-GNTA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T07:40:44", "published_display": "02 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science Faces Court-Ordered Suspension of Corporate Purpose Amendment While Voting Rights Reform Stands", "summary": "Genenta Science S.p.A. announced that the Court of Milan upheld a shareholder resolution introducing a multiple voting rights mechanism, supporting long-term shareholding stability. However, the court suspended an October 2025 resolution that broadened Genenta\u2019s corporate purpose", "url": "https://www.theglobeandmail.com/investing/markets/stocks/GNTA/pressreleases/3017353/genenta-science-faces-court-ordered-suspension-of-corporate-purpose-amendment-while-voting-rights-reform-stands/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T04:10:46", "published_display": "02 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) completes S\u00f2phia High Tech deal and resets key vote", "summary": "Genenta Science (GNTA) has completed its acquisition of a majority equity interest in S\u00f2phia High Tech S.r.l. Shareholders approved the 2025 financial statements and appointed five directors, with co-founder Pierluigi Paracchi re-appointed as Chairman. An Extraordinary Shareholde", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-9c7181ccbefc.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:13", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Genenta Science SpA Sponsored ADR \u2013 FWB:K5F", "summary": "This article provides financial data for Genenta Science SpA Sponsored ADR (FWB:K5F), specifically focusing on its Enterprise Value to EBITDA forward metric. The data is presented by TradingView and indicates a market closed status with no recent trades for the stock on the Frank", "url": "https://www.tradingview.com/symbols/FWB-K5F/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T23:09:42", "published_display": "28 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Genenta Science S.p.A. \u2013 NASDAQ:GNTA", "summary": "This article provides financial information for Genenta Science S.p.A. (NASDAQ:GNTA), specifically focusing on its forward price-to-sales ratio. It appears to be a financial data snippet from TradingView, displaying key metrics for the pharmaceutical company.", "url": "https://www.tradingview.com/symbols/NASDAQ-GNTA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T16:09:42", "published_display": "28 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Genenta Science SpA Sponsored ADR \u2013 FWB:K5F", "summary": "This page displays information regarding the enterprise value to revenue forward for Genenta Science SpA Sponsored ADR (FWB:K5F) on the Frankfurt Stock Exchange. The market was closed, and no trades were recorded. The content is primarily a financial data display from TradingView", "url": "https://www.tradingview.com/symbols/FWB-K5F/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:41:04", "published_display": "28 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Genenta Science S.p.A. \u2013 NASDAQ:GNTA", "summary": "This article focuses on the \"Price to earnings forward\" metric for Genenta Science S.p.A. (NASDAQ: GNTA). It appears to be a financial data page from TradingView, providing an overview of the company's financial information. The content itself, however, does not present any speci", "url": "https://www.tradingview.com/symbols/NASDAQ-GNTA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T05:41:04", "published_display": "28 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta (GNTA) faces court suspension of broad corporate purpose change", "summary": "The Court of Milan has issued an interim order regarding Genenta Science S.p.A. (GNTA), denying the suspension of its multiple voting rights mechanism but temporarily suspending a resolution that broadly amended the company's corporate purpose. The court cited concerns that the c", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-c9f76e01f6bc.html", "source_name": "Stock Titan", "published_at": "2026-06-26T19:39:59", "published_display": "26 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science Sets CEO Severance Terms and Narrows Non-Compete in June 2026", "summary": "Genenta Science S.p.A. (GNTA) has formalized a severance agreement with CEO Pierluigi Paracchi, providing him with a lump-sum payment equivalent to twelve months of his gross remuneration plus a potential 40% annual bonus upon qualifying termination events. The company also narro", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2649620/genenta-science-sets-ceo-severance-terms-and-narrows-non-compete-in-june-2026/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T12:11:34", "published_display": "26 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science SpA Sponsored ADR Actuals & Estimates (NASDAQ:GNTA)", "summary": "The article provides an overview of Genenta Science S.p.A. (NASDAQ:GNTA) on TradingView, focusing on its financial actuals and estimates. It highlights access to reported financial data, analyst estimates across various financial statements, and offers tools to compare actual res", "url": "https://www.tradingview.com/symbols/NASDAQ-GNTA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:11:50", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (NASDAQ: GNTA) revises CEO severance package and non-compete", "summary": "Genenta Science (NASDAQ: GNTA) has updated the severance package and non-compete clause for its CEO, Pierluigi Paracchi, as detailed in a recent 6-K filing. The new \"Parachute Agreement\" stipulates a lump-sum severance payment equivalent to twelve months of his gross remuneration", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-ec26505c341d.html", "source_name": "Stock Titan", "published_at": "2026-06-24T12:41:42", "published_display": "24 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Calls June 29 Shareholder Vote on Name Change, Capital Moves and Reverse Split", "summary": "Genenta Science SpA has scheduled an Ordinary and Extraordinary Shareholders\u2019 Meeting for June 29, 2026, to address significant corporate changes. Shareholders will vote on approving 2025 financial statements, appointing a new Board of Directors, and authorizing share repurchases", "url": "https://www.theglobeandmail.com/investing/markets/stocks/GNTA-Q/pressreleases/2537887/genenta-calls-june-29-shareholder-vote-on-name-change-capital-moves-and-reverse-split/", "source_name": "The Globe and Mail", "published_at": "2026-06-18T20:10:11", "published_display": "18 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science SPA (GNTA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE00T3F4Mk9jRlZ3YXRrTHMxSW5zVmJwZXNzcXprQ1RBS2N4UFRLanE5R2wwV2RRWFhUbjdVYk5kTW5LVS13dHhGcGQxVmlSNVR1d0xQQ1dlYTdIT1RHNFlRMk1FOU11SGpJQVJKWHk0d2o?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T10:22:19+00:00", "published_display": "18 Jun 2026 10:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science SPA (GNTA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Genenta Science SPA (GNTA) as presented on TradingKey. It indicates that GNTA has not distributed any dividends over the past five years and has no recorded stock splits. The page also displays current stoc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnta/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:24", "published_display": "18 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science SPA (GNTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Genenta Science SPA (GNTA), but explicitly states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company. It lists the company's curr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnta/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:24", "published_display": "18 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science SPA (GNTA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Genenta Science SPA (GNTA), highlighting its current stock price, market cap, and analyst target price. While it notes the current stock details, it indicates that relevant data for financial forecasting metrics like EPS, Revenue, an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnta/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:11", "published_display": "18 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science SPA (GNTA) Institutional Confidence", "summary": "This article from TradingKey provides an \"Institutional Confidence\" overview for Genenta Science SPA (GNTA), listing key shareholders and their respective shareholdings, including recent changes. The stock closed at $1.820 USD, down 2.67%, and has a market cap of $43.41M. Citadel", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnta/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:11", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science Regains Compliance with Nasdaq Minimum Bid Price Rule", "summary": "Genenta Science (GNTA) announced it has regained compliance with Nasdaq's minimum bid price rule of $1.00 per share, resolving a previous non-compliance issue. This ensures the company's continued listing on the Nasdaq Capital Market, preserving market confidence and access to pu", "url": "https://www.theglobeandmail.com/investing/markets/stocks/GNTA-Q/pressreleases/2517030/genenta-science-regains-compliance-with-nasdaq-minimum-bid-price-rule/", "source_name": "The Globe and Mail", "published_at": "2026-06-17T13:10:38", "published_display": "17 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) sets June meeting on name change and reverse split", "summary": "Genenta Science (GNTA) has scheduled an all-virtual ordinary and extraordinary shareholders' meeting for June 29, 2026, with a potential second call on June 30, 2026. Shareholders will vote on approving financial statements, appointing a new Board, authorizing treasury share tran", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-4a3aa3bf231f.html", "source_name": "Stock Titan", "published_at": "2026-06-17T13:09:12", "published_display": "17 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science regains compliance with Nasdaq minimum bid price rule By Investing.com", "summary": "Genenta Science S.p.A. announced it has regained compliance with Nasdaq's minimum bid price requirement. The company's American Depositary Shares (ADSs) maintained a closing bid price at or above $1.00 for ten consecutive business days, resolving a previous non-compliance issue. ", "url": "https://za.investing.com/news/sec-filings/genenta-science-regains-compliance-with-nasdaq-minimum-bid-price-rule-93CH-4330849", "source_name": "Investing.com South Africa", "published_at": "2026-06-16T19:40:49", "published_display": "16 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (NASDAQ: GNTA) regains Nasdaq minimum bid price compliance", "summary": "Genenta Science (NASDAQ: GNTA) has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company's American Depositary Shares (ADSs) traded at or above $1.00 per share for 10 consecutive business days from June 1-12, 2026, resolving a previous", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-575d6471741f.html", "source_name": "Stock Titan", "published_at": "2026-06-16T13:39:21", "published_display": "16 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GNTA - Genenta Science SpA ADR Options", "summary": "This page provides an overview of Genenta Science SpA ADR (GNTA) stock options, including financial data, performance metrics, and key statistics. It details the company's market cap, enterprise value, income, sales, and various ratios, alongside insider and institutional ownersh", "url": "https://finviz.com/stock?t=GNTA&ty=oc", "source_name": "Finviz", "published_at": "2026-06-12T04:40:46", "published_display": "12 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GNTA Stock Sees Volatile Spike As Traders Eye Key Levels", "summary": "Genenta Science S.p.A. (NASDAQ: GNTA) stock surged over 100% due to progress in its oncology trial, attracting significant trader attention. The company, a micro-cap biotech, has little revenue but holds a solid balance sheet, making it a speculative bet on future potential rathe", "url": "https://www.timothysykes.com/news/genenta-science-spa-gnta-news-2026_06_01/", "source_name": "Timothy Sykes", "published_at": "2026-06-01T13:09:44", "published_display": "01 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GNTA Stock Explodes On Volume As Traders Scan Biotech Charts", "summary": "Genenta Science S.p.A. (GNTA) stock surged by 85.5%, driven by regulatory and clinical progress, turning it into a low-float momentum play for active traders. Despite its small revenue, GNTA has a solid balance sheet and trades near its book value, making its chart action and vol", "url": "https://stockstotrade.com/news/genenta-science-spa-gnta-news-2026_06_01/", "source_name": "StocksToTrade", "published_at": "2026-06-01T10:02:00", "published_display": "01 Jun 2026 10:02", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science Closes All-Share Acquisition of Remaining Stake in A.T.C.", "summary": "Genenta Science has completed an all-share acquisition of the remaining 80.5% stake in A.T.C. S.r.l., solidifying its full ownership. The \u20ac9.6 million purchase was settled by issuing new Genenta ordinary shares to A.T.C. shareholders, who are subject to a 36-month lock-up period ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/GNTA-Q/pressreleases/2219172/genenta-science-closes-all-share-acquisition-of-remaining-stake-in-a-t-c/", "source_name": "The Globe and Mail", "published_at": "2026-05-31T13:08:56", "published_display": "31 May 2026 13:08", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) Surges on High Volume: Key Levels and Potential Drivers - Quality Factor", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPcl95bUw0dVI3aHl6RXc4Y1FsQkp6QS1HcFZmS1BoeE11YW81Uko5MFhjUzk0V2JlQThKdjl2VzhYTy1ndnMyamFOclBuZnJUODVTXzQyUFVGWWlKY19WdXVRODBlZmlUbmNrU2l1TEJkVG9nd01Md2VDM1hGbkxYLWxESUNXcEFzS1Y1MmxKemVYR09qTHItYWs4U1BCeUZWWUJYbFZFcUVRY3FUYVV4WDY3Z20wa0JMaHo2UVlRbw?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) takes full control by acquiring remaining 80.5% of A.T.C.", "summary": "Genenta Science (GNTA) has acquired the remaining 80.5% equity ownership of A.T.C. S. from its existing shareholders, taking full control. The transaction, finalized on May 29, 2026, was governed by an Amendment Agreement and approved by Genenta's board on May 18, 2026. Key terms", "url": "https://www.stocktitan.net/sec-filings/GNTA/6-k-genenta-science-s-p-a-current-report-foreign-issuer-945ff04241b8.html", "source_name": "Stock Titan", "published_at": "2026-05-29T19:38:44", "published_display": "29 May 2026 19:38", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) Surges 9%: Testing Key Resistance at $0.95 - Trend Continuation Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPdGhlWUVTaG5zRTE1czZqRW9oZGp4eFphcWtQQ045WjYxcDdxU09TTEhSLUJpaFBpOVlBX3JPMDFFeUdTWDVEaGh4Ry1rZ2VieFJpTlp3VV9EZ2lleVh6NUNDRURKTXlfRURWS2dzeUZmX2RZTHZ2RGNPMDRNUVRNSlRfNFZuMTQyUTZnOHN1T1hWU1Mtbk8tMmFTLXluS1dHLVN1X05EbWxBZzAzaVB3?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) Surges 9%: Testing Key Resistance at $0.95 - Median Line", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOMnF3bDZrS3dZQ0N4b042QmtCcGx3dDM1S3dqYnV4MEVfSm1nRnJ6NGVETWVNNlptT2hvR2czTGJqbjN2MHNmMmFGWG40M01JUlVyaWl4Z3ZBYUUyY1NxZjBHUVBVMzZkdW5OZXNWQjl6Smk3Y0R6cUdpSXJwZlpGbVlHdnlsYlh0S1BmZzdNRTVvTUU2c0p1dkEyZUV1SjRYTFE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science (GNTA) Holds Steady at $0.60 Amid Low Volatility - Mid Cap Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNaDBVRDRUZm10aUQ0RzRQZXJHbFdnY0xfd3FnaTBaenNzZ0xxbWtmVTlSSUdGUjloQ0k5cWh0aTRPZUZIZGNRakdVdHJJSEdQdUhUTmRvNXFqRTl2UllEelh1V0ZYWDFPZm05RlotUHk1dzlBazJLVzgzc0dxS2FkWGtpQlFIVEpuRzZid2NlN3dHMWpqMkVONlV6Vm94V3J6SG5zeU02c25FbDQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta signs Definitive Agreements with Sophia High Tech", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/genenta-signs-definitive-agreements-sophia-110000653.html", "source_name": "GlobeNewswire", "published_at": "2026-04-23T11:00:00+00:00", "published_display": "23 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQaUJfcTdWRC1BYU5iUW5SSXM4cENlak1JLTBERDhfeUtsNVpaOVluS0VqTnFJWkwyTnhkVUJ5ZnVtTjRPcTB0YnhzWlVHUHF6eUcwa1VVVTlwOEZwQ3U2WndDdHJXR3dLN0xxbTJVR294akF2R0xyV2hXUEYzckRlNy1VRW41dw?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science Spa (GNTA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1UcEdKXzN4em9ySWxudzg1VXpzM3d4VGJ2Rk9FNHFEc2tvTGU0bjBUZmlkdUZJSTZoT0laRi1JSTJ3V1RLaFBqUnh4WDB1MGp5ZGpR?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T17:33:47+00:00", "published_display": "24 Apr 2025 17:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genenta Science S.p.A.: Shareholders Board Members Managers and Company Profile | US36870W1009", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNVHZZNDkwRU1maXF1Vlh6YVJKcldWMXhVWTFKdzZfRnMzaE8xNVE0RXUwTVVtRnNFRUNuUzdDYzFXSEhWSzZRNGdoTU9EMThxZWtqb01rQUd1YVNQVTRUNXFVYTdmMmRlVWJDRlFWRVpvODlKT2ZNemFtbXhTR19xa2hVVkNRejh2cTI0?oc=5", "source_name": "marketscreener.com", "published_at": "2021-12-17T21:21:52+00:00", "published_display": "17 Dec 2021 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 82, "total_relevant": 48, "sentiment_summary": {"positive": 13, "negative": 4, "neutral": 31, "score": 54, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 15.4, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 1.5, "latest_week": "2026-07-10", "one_week_move": -12.8, "four_week_move": -19.8, "twelve_week_move": 105.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.244206, "market_dynamics_buy_signal": false, "relative_strength": -35.564125, "fair_value_gap": -57.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.8803, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-12.8% over one week, -19.8% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 8}, {"label": "Market source", "count": 6}, {"label": "The Globe and Mail", "count": 5}, {"label": "TradingKey", "count": 5}, {"label": "dars.gov.et", "count": 2}, {"label": "Donan\u0131mHaber", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 16}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-12.8% over one week, -19.8% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Genenta Science Regains Full Effectiveness of Corporate Purpose Amendment After Milan Court Ruling"}], "updated_at": "2026-07-16T11:50:58.940718+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}